Suppr超能文献

在一名患有先天性抗凝血酶III(AT III)缺乏症且正在接受定期血液透析的慢性肾衰竭患者中抗凝剂的选择。

Choice of anticoagulant in a congenital antithrombin III (AT III)-deficient patient with chronic renal failure undergoing regular haemodialysis.

作者信息

Matsuo T, Yamada T, Yamanashi T, Kodama K

机构信息

Hyogo Prefectural Awaji Hospital, Sumoto, Japan.

出版信息

Clin Lab Haematol. 1989;11(3):213-9. doi: 10.1111/j.1365-2257.1989.tb00211.x.

Abstract

We describe a 43-year-old male patient with congenital antithrombin III deficiency requiring haemodialysis due to extension of venous thrombus from recurrent deep vein thrombosis. During dialysis with adequate heparinization, the patient often revealed clot formation in the extracorporeal circuit resulting in unexpected discontinuation of dialysis. When either a combination of antithrombin III concentrate plus heparin or the newly developed synthetic antithrombin preparation, MD805, was infused during dialysis, he could be uneventfully dialysed with either of the two regimens. The functional antithrombin III activity with MD805 increased to the same level as that obtained with antithrombin III concentrate, and it was possible to achieve an antithrombotic effect, as measured from the APTT and thrombin-antithrombin III complex with MD805 during and after dialysis. We thus found that MD805 could be used as an anticoagulant drug when an AT III-deficient patient required anticoagulation in the extracorporeal circulation.

摘要

我们描述了一名43岁的男性患者,因复发性深静脉血栓形成导致静脉血栓扩展而需要进行血液透析,该患者患有先天性抗凝血酶III缺乏症。在进行充分肝素化的透析过程中,患者体外循环中经常出现血栓形成,导致透析意外中断。当在透析期间输注抗凝血酶III浓缩物加肝素的组合或新开发的合成抗凝血酶制剂MD805时,两种方案均可使他顺利进行透析。使用MD805时的功能性抗凝血酶III活性增加到与抗凝血酶III浓缩物相同的水平,并且从透析期间和透析后使用MD805时的活化部分凝血活酶时间(APTT)和凝血酶 - 抗凝血酶III复合物测量,有可能实现抗血栓形成效果。因此,我们发现当抗凝血酶III缺乏的患者在体外循环中需要抗凝时,MD805可作为抗凝药物使用。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验